Which country is Asciminib developed in and its R&D background is introduced?

Asciminib (also known as Asciminib) is a new anti-cancer targeted drug developed by an American pharmaceutical company. The drug was developed by **Novartis (Novartis) ** in the United States and aims to provide a new treatment option for patients with chronic myelogenous leukemia (CML). As a world-renowned pharmaceutical company, Novartis has accumulated rich experience in the research and development of targeted drugs for hematological tumors. Asciminib is its important innovation in the field of BCR-ABL targeting.

The research and development background of Asciminib stems from in-depth research on the drug resistance mechanism of chronic myelogenous leukemia. Traditional tyrosine kinase inhibitors (TKI) such as imatinib and dasatinib may experience resistance or relapse in some CML patients. AsciminibAs the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitors, by binding to the sarcosyl binding pocket of the BCR-ABL enzyme, achieve a different mechanism of action from traditional ATP binding site inhibitors, thereby effectively overcoming the drug resistance problem.

The clinical development of Asciminib began in the 2010 years, and has gone through phase I and II clinical trials to verify its safety and efficacy. Studies have shown that the drug has significant efficacy and is well tolerated in patients with CML who have previously been resistant to first- or second-line TKIs. It then entered Phase III clinical trials to further evaluate its long-term efficacy and safety in chronic phase CML patients, providing solid data support for its marketing applications in the United States and other countries.

The research and development of Asciminib not only provides new treatment options for CML patients, but also promotes the innovation of targeted drugs for drug resistance mechanisms. Its unique target and ability to overcome drug resistance make it a global CMLAn important breakthrough in the field of treatment. With the advancement of clinical trials and approvals in many countries, Asciminib is expected to improve the prognosis of drug-resistant CML patients globally and become a new benchmark for targeted therapy in the context of precision medicine.

Reference materials:https://www.drugs.com/